ArticleBMC cancer2010

Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?

Tibor Bakács et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.